TABLE 4

Biodistribution of Radiolabeled J591 mAb in Patients with Prostate Cancer: ¹¹¹In vs. ¹⁷⁷Lu

Organ	%ID of ¹¹¹In-DOTA-J591 (n = 26)					%ID of ¹⁷⁷Lu-DOTA-J591* (n = 23)
Organ		Day 0	Day 3	Day 6	Day 0	Day 2	Day 7	Day 13
Whole body	100	81.0 ± 5.5	66.1 ± 18	100	91.6 ± 10	69.8 ± 9.5^†	41.6 ± 9.0
Remainder	52.3 ± 5.7	39.4 ± 7.1	24.9 ± 16.8	57.5 ± 6.4^‡	51.5 ± 7.2	34.7 ± 6.9^‡	18.4 ± 5.2
Heart contents	8.9 ± 2.3	4.5 ± 1.0	3.4 ± 1.2	8.8 ± 2.2^†	5.7 ± 1.3	3.1 ± 0.9^†	1.9 ± 0.4
Lungs	9.0 ± 2.0	5.5 ± 1.5	4.4 ± 1.7	6.9 ± 1.9^‡	4.9 ± 1.4	3.1 ± 0.7^‡	2.2 ± 0.6
Liver	14.7 ± 3.2	24.1 ± 5.9	28.0 ± 7.8	15.0 ± 3.8^†	20.3 ± 6.2	23.7 ± 7.0^§	16.5 ± 4.8
Spleen	10.9 ± 5.0	3.0 ± 2.2	1.2 ± 1.1	7.4 ± 2.4^‡	3.6 ± 1.5	0.6 ± 0.4^§	0.1 ± 0.1
Kidneys	2.4 ± 0.8	3.0 ± 0.8	2.5 ± 0.7	2.2 ± 0.5^†	3.3 ± 0.9	2.5 ± 0.5^†	1.3 ± 0.4

↵* Statistical significance of the difference between ¹⁷⁷Lu and ¹¹¹In was calculated for values on day 0 and day 6–7.
↵^† P > 0.1.
↵^‡ P < 0.01.
↵^§ P < 0.05.